Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura : A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura
© 2021 Wiley Periodicals LLC..
BACKGROUND: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease characterized by the presence of anti-ADAMTS13 autoantibodies. Achieving accurate information on incidence and customary disease management is important to provide appropriate diagnostic and therapeutic resources. The aim of this study was to determine the incidence and outcomes of iTTP in Spain.
STUDY DESIGN AND METHODS: A cross-sectional survey was carried out among Spanish hospitals, focused on iTTP patients ≥16 years old attended between 2015 and 2017, and those at follow-up before that interval. Incidence, prevalence, mortality, refractoriness, exacerbations, treatment complications, relapses, and sequelae were estimated.
RESULTS: Forty-two hospitals covering roughly 20 million inhabitants answered the survey and reported 203 episodes (138 newly-diagnosed and 65 relapses), of which 193 (95.1%) were treated. Incidence was 2.67 (95% CI 1.90-3.45) patients per million inhabitants per year and prevalence 21.44 (95% CI% 19.10-23.73) patients per million inhabitants. At diagnosis, ADAMTS13 activity and anti-ADAMTS13 autoantibody were measured in 97% and 84.3% of reported episodes, respectively. Fifteen patients (7.4%) died as a direct consequence of iTTP, 6 of them before receiving any iTTP-specific treatment. Thirty-one (16.1%) of the 193 treated episodes were refractory to plasma exchange and corticosteroids, and 51 (26.4%) suffered at least one exacerbation.
CONCLUSION: iTTP incidence and prevalence were somewhat higher than those documented in neighboring countries. Together with data on treatments and outcomes, this information will allow us to better estimate what is needed to improve diagnosis and prognosis of iTTP patients in Spain.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of clinical apheresis - 36(2021), 4 vom: 28. Aug., Seite 563-573 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pascual-Izquierdo, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ADAMTS13 |
|---|
| Anmerkungen: |
Date Completed 24.01.2022 Date Revised 24.01.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jca.21894 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323363679 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323363679 | ||
| 003 | DE-627 | ||
| 005 | 20231225184023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jca.21894 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1077.xml |
| 035 | |a (DE-627)NLM323363679 | ||
| 035 | |a (NLM)33780553 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pascual-Izquierdo, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura |b A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.01.2022 | ||
| 500 | |a Date Revised 24.01.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease characterized by the presence of anti-ADAMTS13 autoantibodies. Achieving accurate information on incidence and customary disease management is important to provide appropriate diagnostic and therapeutic resources. The aim of this study was to determine the incidence and outcomes of iTTP in Spain | ||
| 520 | |a STUDY DESIGN AND METHODS: A cross-sectional survey was carried out among Spanish hospitals, focused on iTTP patients ≥16 years old attended between 2015 and 2017, and those at follow-up before that interval. Incidence, prevalence, mortality, refractoriness, exacerbations, treatment complications, relapses, and sequelae were estimated | ||
| 520 | |a RESULTS: Forty-two hospitals covering roughly 20 million inhabitants answered the survey and reported 203 episodes (138 newly-diagnosed and 65 relapses), of which 193 (95.1%) were treated. Incidence was 2.67 (95% CI 1.90-3.45) patients per million inhabitants per year and prevalence 21.44 (95% CI% 19.10-23.73) patients per million inhabitants. At diagnosis, ADAMTS13 activity and anti-ADAMTS13 autoantibody were measured in 97% and 84.3% of reported episodes, respectively. Fifteen patients (7.4%) died as a direct consequence of iTTP, 6 of them before receiving any iTTP-specific treatment. Thirty-one (16.1%) of the 193 treated episodes were refractory to plasma exchange and corticosteroids, and 51 (26.4%) suffered at least one exacerbation | ||
| 520 | |a CONCLUSION: iTTP incidence and prevalence were somewhat higher than those documented in neighboring countries. Together with data on treatments and outcomes, this information will allow us to better estimate what is needed to improve diagnosis and prognosis of iTTP patients in Spain | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ADAMTS13 | |
| 650 | 4 | |a Spain | |
| 650 | 4 | |a immune-mediated thrombotic thrombocytopenic purpura | |
| 650 | 4 | |a incidence | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a ADAMTS13 Protein |2 NLM | |
| 650 | 7 | |a EC 3.4.24.87 |2 NLM | |
| 650 | 7 | |a ADAMTS13 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.24.87 |2 NLM | |
| 700 | 1 | |a Del Rio-Garma, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a de la Rubia, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Viejo, Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Mingot, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Cid, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Solanich, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Sojo, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Martín-Sánchez, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a García-Gala, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Alonso, Nieves |e verfasserin |4 aut | |
| 700 | 1 | |a González, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Seguí, Inés |e verfasserin |4 aut | |
| 700 | 1 | |a Goterris, Rosa |e verfasserin |4 aut | |
| 700 | 1 | |a Guerra, Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a García-Candel, Faustino |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Docampo, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Antelo, María Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a Salgado-Barreira, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Salinas, Ramón |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish Apheresis Group (GEA) and Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT) |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical apheresis |d 1993 |g 36(2021), 4 vom: 28. Aug., Seite 563-573 |w (DE-627)NLM012676969 |x 0733-2459 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:4 |g day:28 |g month:08 |g pages:563-573 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jca.21894 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 4 |b 28 |c 08 |h 563-573 | ||